Fig. 4From: Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registryPercentage change in median serum alkaline phosphatase over time in (a) patients with metastatic disease at baseline and (b) patients with no prior hormonal therapyBack to article page